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INTRODUCTION

On April 22, 2018, eighteen-year-old Deanna Recktenwald stared
death square in the face and did not even know it, at least not until her
robotic sidekick—her Apple Watch—notified her to seek immediate medical
attention. 1 As Deanna quietly and calmly sat in church, her smart watch
pinged her out of nowhere, alerting her that her resting heart rate had
skyrocketed from a normal rate of sixty to one hundred beats per minute to a
rate of one hundred ninety beats per minute. 2 Her watch immediately
instructed her to reach the nearest hospital and, upon arrival, emergency
room physicians performed a series of tests confirming that Deanna’s smart
watch was correct—her heart rate was abnormally high. 3 Within hours,
medical professionals told Deanna that her Apple Watch “helped catch a
serious condition from which she was unaware she was suffering,” a genetic
condition known as Alport system. 4 The condition was causing Deanna’s
kidneys to function at twenty percent and fail. 5 Doctors warned her that she
was lucky to be alive and told her that if the smart watch had not alerted her
to the symptoms, she would have required an emergency kidney transplant. 6
Deanna’s story is not unique, but is one of the many stories
considered at the start of a technological revolution in the healthcare world—
an Artificial Intelligence (“AI”) revolution.7 The words AI and revolution in
one sentence may evoke futuristic images of robotic machines who become
more innovative and advanced than their creators, ultimately deciding to
annihilate civilization. 8 But, in reality, imagining a dystopian future with an
1.
Teen’s Life Saved by Apple Watch That Alerted Her Heart Condition,
INSIDE EDITION: NEWS (May 4, 2018, 8:23 AM), http://www.insideedition.com/teens-lifesaved-apple-watch-alerted-her-heart-condition-43024.
2.
Id.
3.
Id.
4.
Id.
5.
Christina Capatides, Teen's Apple Watch May Have Saved Her Life, CBS
NEWS (May 2, 2018, 6:18 PM), http://www.cbsnews.com/news/teens-apple-watch-may-havesaved-her-life/.
6.
Id.
7.
See id.; Carrie Marshall, The Doctor on Your Wrist: How Wearables Are
Revolutionizing
Healthcare,
TECHRADAR:
NEWS
(July
7,
2018),
http://www.techradar.com/news/the-doctor-on-your-wrist-how-wearables-are-revolutionizinghealthcare; Michael Reilly, With a Little AI, Apple Watch May Be Able to Spot a Heart
TECH.
REV.:
CONNECTIVITY
(May
12,
2017),
Problem,
MIT
http://www.technologyreview.com/s/607867/with-a-little-ai-apple-watch-may-be-able-to-aspot-heart-problem/. In fact, the Apple Watch is credited with saving over three lives by
alerting its wearers to seek immediate medical help. Marshall, supra.
8.
Scott Bennett & Leeann Habte, Artificial Intelligence in Health Care:
Welcome to the Machine, AHLA CONNECTIONS, June 2018, at 16, 17.
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impending doom is not necessary to see just how AI can change the way we
live our lives. 9 Wearables such as the Apple Watch or Fitbit are no longer
engineered to just monitor how many steps a user takes in one day or a user’s
resting heart rate; they employ a form of AI technology that mimics the
human brain to detect irregular heartbeats and spot health issues such as high
blood pressure, sleeping issues, and even atrial fibrillation. 10 AI has turned
these flashy devices from fashion into robotic doctors on your wrist and that
is only a sliver of how healthcare is beginning to incorporate data-driven
intelligence to save lives. 11
The very first glimpse of AI occurred in the late 1950s. 12 One of the
brightest minds of Dartmouth, professor John McCarthy, brought together a
group of computer scientists in a workshop, known today as the Dartmouth
Workshop, to create his vision of getting computers to learn language just as
humans do. 13 McCarthy’s ideas on computer learning led the creation of the
field of AI. 14 From the 1950s on, the field developed and never stopped. 15
From computers that played checkers to the first computer world chess
champion, milestone after milestone was reached as computers completed
tasks, just like humans. 16
AI has come a long way since, but as innovation continues to move
at the speed of light, complex issues begin to present themselves. 17 While AI
is taking humankind into the future—left, right, and center—AI is being
applied to various industries, but laws and regulations are struggling to keep

9.
Id.
10.
Megan Molteni, With AI, Your Apple Watch Could Flag Signs of
Diabetes, WIRED: SCI. (Feb. 7, 2018, 10:00 AM), http://www.wired.com/story/with-ai-yourapple-watch-could-flag-signs-of-diabetes/; see also This Artificial Intelligence Model Mimics
TIMES
(July
24,
2018,
12:22
PM),
Human
Brain,
ECON.
http://www.economictimes.indiatimes.com/news/science/this-artificial-intelligence-modelmimics-human-brain/articleshow/65115249.cms.
11.
See Jane R. Bambauer, Dr. Robot, 51 U.C. DAVIS L. REV. 383, 388
(2017); Marshall, supra note 7.
12.
Tom Simonite, The Wired Guide to Artificial Intelligence, WIRED: BUS.
(Feb. 1, 2018, 9:22 AM), http://www.wired.com/story/guide-artificial-intelligence/.
13.
Id.
14.
Id.
15.
See id.
16.
Id.; see also Pavel Hamet & Johanne Tremblay, Artificial Intelligence in
Medicine, 69 METABOLISM CLINICAL & EXPERIMENTAL, S36, S37 (2017).
17.
See Michael Guihot et al., Nudging Robots: Innovative Solutions to
Regulate Artificial Intelligence, 20 VAND. J. ENT. & TECH. L. 385, 394 (2017); Richard A.
Merrill, The Architecture of Government Regulation of Medical Products, 82 VA. L. REV.
1753, 1753–54 (1996).
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tempo with the growth and change of such technological advancement. 18
One of the biggest and most worrisome issues facing regulatory agencies is
AI as applied to the healthcare world, its medical devices, and its drugs. 19
The daunting task of determining what is the best route to regulate AI
medicine so it is safe and effective falls to the purview of the United States
Food and Drug Administration (“FDA”). 20 While the FDA’s traditional
reaction to change in the healthcare world is to wait out innovation until a
public health crisis forces regulatory amendment, history will not repeat
itself this time. 21 The FDA has issued guidance and attempted to get ahead
of innovation, promoting AI in healthcare—but that begs the question, is
caution warranted? 22
This Comment will first provide an introduction to AI, going indepth on its history and how it has rapidly developed in the medical
culture. 23 More specifically, the Comment will discuss the types of AI,
breaking down the difference between machine-learning (“ML”) and deeplearning (“DL”) intelligence. 24 Part III of this Comment will then discuss the
FDA in great detail, providing a historical overview of how the FDA has
developed since its establishment and how it has reacted to previous
healthcare advancements. 25 Additionally, it will discuss how the FDA
currently regulates medical devices and drug discoveries. 26 Part IV of this
Comment will explain the FDA’s newest proposed regulatory guidelines for
how to regulate AI’s incorporation into healthcare devices and the risks of
regulating AI so quickly. 27 Finally, Part V will offer a conclusion. 28
II.

AN INTRODUCTION TO AI

“The development of full [AI] could spell the end of the human race
. . . . [AI] would take off on its own, and re-design itself at an ever-increasing
18.
Asokan Ashok, The Impact of Artificial Intelligence in Healthcare,
MEDIUM (Aug. 24, 2017), http://www.medium.com/@Unfoldlabs/the-impact-of-artificialintelligence-in-healthcare-4bc657f129f5.
19.
Id.
20.
See Bambauer, supra note 11, at 385; Ashok, supra note 18.
21.
See Merrill, supra note 17, at 1761–62; Ashok, supra note 18.
22.
See Ashok, supra note 18; Aaron Gin & Bryan Helwig, FDA Signals
Fast-Track Approval for AI-Based Medical Devices, BLOOMBERG L. (May 9, 2018, 2:26 PM),
http://news.bloomberglaw.com/tech-and-telecom-law/fda-signals-fast-track-approval-for-aibased-medical-devices-1/.
23.
See infra Section II.A.
24.
See infra Section II.A.2–3.
25.
See infra Section III.A.
26.
See infra Section III.B.
27.
See infra Part IV.
28.
See infra Part V.
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rate. Humans, who are limited by slow biological evolution, [could not]
compete, and would be superseded.” 29
A.

History of AI

Modern society is no stranger to the term AI. 30 The reality is that AI
is not a novel concept; since the 1950s, AI has been embedded in our culture
as an idea of science fiction, with everything from onscreen entertainment to
education. 31 The common perception of AI is derived from box-office hits
such as Star Wars, I, Robot, Blade Runner, and Interstellar, where “AI
beings who . . . challenge[] what it means to be human” have been brought to
the screen of modern society. 32 But what is AI? 33 Where did this
unorthodox and critically important scientific idea that is going to affect so
many industries come from? 34 Before embarking on AI’s origin story—and
how it became a field in need of its own regulation—it is important to define
what intelligence is first.35 In terms of mankind, intelligence has been
defined as characteristics comprised of “consciousness, self-awareness,
language use, the ability to learn, the ability to abstract, the ability to adapt,
and the ability to reason.” 36 Calculations or approximations of such
characteristics shape the benchmark of attempts to recreate or mimic such
intelligence, also known as AI. 37 Understanding what the threshold criteria
should be for a simulation possessing such intellectual qualities to be deemed
an AI is precisely what Dartmouth professor, John McCarthy, attempted to
define in 1956 when he coined the term AI. 38
29.
Bernard Marr, 28 Best Quotes About Artificial Intelligence, FORBES (July
25, 2017, 12:28 AM), http://www.forbes.com/sites/bernardmarr/2017/07/25/28-best-quotesabout-artificial-intelligence/#50783d374a6f.
30.
See Michael Hogan & Greg Whitmore, The Top 20 Artificial Intelligence
(Jan.
8,
2015,
7:29
PM),
Films
—
in
Pictures,
GUARDIAN
http://www.theguardian.com/culture/gallery/2015/jan/08/the-top-20-artificial-intelligencefilms-in-pictures; Simonite, supra note 12.
31.
See Ashok, supra note 18; Hogan & Whitmore, supra note 30; Simonite,
supra note 12.
32.
Hogan & Whitmore, supra note 30.
33.
See Guihot et al., supra note 17, at 393–96; Simonite, supra note 12.
34.
See Simonite, supra note 12.
35.
Guihot et al., supra note 17, at 393.
36.
Id.
37.
Id. at 393–94.
38.
Id.; Simonite, supra note 12. The pioneers of AI date back to names such
as Alan Turing and John von Neumann who focused on strong AI. M. Tim Jones, A
Beginner’s Guide to Artificial Intelligence, Machine Learning, and Cognitive Computing,
IBM DEVELOPER (June 1, 2017), http://developer.ibm.com/articles/cc-beginner-guidemachine-learning-ai-cognitive/.
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McCarthy “defined AI as ‘the science and engineering of making
intelligent machines, especially intelligent computer programs.’” 39 He was
careful not to confine intelligence in AI to an exact replication of human
intelligence; instead, McCarthy contended that machines had the ability to
exhibit other intelligences that required “much more computing than people
can do.” 40 McCarthy created and coined the field of AI by approaching a
small group of colleagues and asking them to study the possible idea of
making “machines do things [such as] use language.” 41 The study has been
referred to as the Dartmouth Workshop, recognized for “[giving] birth to
what developed into a new interdisciplinary research area.” 42 The work
accomplished at the Dartmouth Workshop “focused on solving fairly abstract
problems in math and logic” that resulted in the algorithms that we know and
see in AI today. 43
Early AI research, such as the Dartmouth Workshop, created a hype
in the development of the AI field that resulted in computers starting “to
solve . . . complex mathematical problems.” 44 Computer scientists began to
develop “[i]nstruments with increasing computational power. 45 These
discoveries paved the way for technological achievements such as IBM’s
Deep Blue winning the title of World Chess Champion in 1997, when it
defeated its human opponent, Gary Kasparov. 46 Today, AI is treated as a
subset of the engineering field that implements innovative concepts and
“solutions to []solve complex challenges.” 47
1.

What is AI?

In today’s day and age, AI plays a role by “powering . . . technology
that impacts people’s daily lives.” 48 AI is the substructure of nearly every
39.
Guihot et al., supra note 17, at 394 (quoting John McCarthy, What Is
Artificial
Intelligence?,
STAN.
U.
2
(Nov.
12,
2007,
2:05
AM),
http://jmc.stanford.edu/articles/whatisai/whatisai.pdf).
40.
Id.; McCarthy, supra note 39, at 3.
41.
Simonite, supra note 12.
42.
Hamet & Tremblay, supra note 16, at S37; Simonite, supra note 12.
43.
Simonite, supra note 12. An algorithm is a program that evaluates data
and executes given instructions. See Jeff Goodell, Inside the Artificial Intelligence
Revolution: A Special Report, Pt. 1, ROLLING STONE: CULTURE (Feb. 29, 2016, 2:05 PM),
http://www.rollingstone.com/culture/culture-news/inside-the-artificial-intelligence-revolutiona-special-report-pt-1-118333/.
44.
Hamet & Tremblay, supra note 16, at S37.
45.
Id.
46.
Simonite, supra note 12.
47.
Hamet & Tremblay, supra note 16, at S37.
48.
Understanding the Black Box of Artificial Intelligence, SENTIENT: BLOG
(Jan. 9, 2018), http://www.sentient.ai/blog/understanding-black-box-artificial-intelligence/.
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website, cellphone, and tool that we use today—without it, iPhones would
not ring, iPads would not turn on, and Twitter would not tweet. 49 So what
exactly is AI? 50 Well, simply put, it is a complex “mathematical equation
that [instructs] a computer [on] what [task] to perform.” 51 The guide to
breaking down AI algorithms can be complex and dense because these
mathematical equations have many different parts to them. 52 In its earliest
stages, the main focus on the development of AI was to get a machine to
“perform any intellectual task that a human could [do].” 53
This
developmental focus became known as strong AI or Artificial General
Intelligence (“AGI”), which does not exist yet in today’s society. 54 AGI is
defined or referred to as machine sentience or the “possess[ion] [of] a
reasonable degree of self-understanding, . . . the ability to solve a variety of
complex problems in a variety of contexts, and [the ability to] learn to solve
new problems that [it] didn’t know about at the time of [its] creations.” 55
Due to a lack of progress in the field of AI for many years, an area in the
field of AI was created on its own—one which is prevalent in our everyday
lives—known as weak or narrow AI. 56 This type of AI is exactly what it
sounds like: AI that is not real and “focused on [carrying out] a single
task.” 57 Narrow AI is what “is used to recommend what films you watch on
Netflix or what songs you listen to on Spotify,” or even to recommend a
course of medical treatment; it essentially powers unexceptional machinery
with exceptional algorithms. 58
2.

ML

However, achieving such technological advancement in making
machines smart did not occur without digression from the original goal of

49.
See id.; Goodell, supra note 43.
50.
Jason Chung & Amanda Zink, Hey Watson — Can I Sue You for
Malpractice? Examining the Liability of Artificial Intelligence in Medicine, ASIA PAC. J.
HEALTH L. & ETHICS, Mar. 2018, at 51, 53.
51.
Goodell, supra note 43.
52.
See Jones, supra note 38. The definitions, or lack thereof, is a discussion
beyond the scope of this Comment.*
53.
Id.
54.
Guihot et al., supra note 17, at 396.
55.
ARTIFICIAL GENERAL INTELLIGENCE vi (Ben Goertzel & Cassio Pennachin
eds., 2007); Chung & Zink, supra note 50, at 53.
56.
Chung & Zink, supra note 50, at 53; Jones, supra note 38.
57.
Chung & Zink, supra note 50, at 53.
58.
Understanding the Black Box of Artificial Intelligence, supra note 48;
Chung & Zink, supra note 50, at 54.
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AI. 59 During the early years of AI development and research, scientists and
engineers found themselves torn between AI and AGI, ultimately stumbling
upon a new type of algorithm known as ML. 60 ML, originally developed in
the 1980s, quickly became a leading subset of AI research. 61 The goal
behind ML is to give machines, especially computers, “the ability to learn
and build models so . . . they [are able to] perform activities [such as]
prediction within specific domains.” 62 But, what is ML? 63 Is it a technology
or a separate type of intelligence? 64 Google defines ML as:
A program or system that builds—[or] trains—a
predictive model from input data. The system uses the learned
model to make useful predictions from new—[or] never-beforeseen—data drawn from the same distribution as the one used to
train the model. [ML] also refers to the field of study concerned
with these programs or systems. 65

ML can be thought of as types of AI math equations that tell a
computer what to do. 66 These math equations are based off of algorithms
that “have been around for thousands of years and [used for basic] modern
computer[s].” 67 Put simply, these equations put data in the computer and the
“algorithm spits out a result.” 68 What is different about ML algorithms is
that the computers write their own algorithms. 69 How does this work? 70 If
you wanted to teach a computer how to perform an MRI of a brain, first you
would write an algorithm that teaches the computer the controls of the MRI
machine and input the data. 71 Next, you would tell the computer how and
what parts of the brain you want scanned—known as the result. 72 Finally,
the computer will give its own algorithm that tells the MRI machine how to
59.
See Hamet & Tremblay, supra note 16, at S37; Goodell, supra note 43;
Jones, supra note 38.
60.
See Jones, supra note 38.
61.
Id.
62.
Id.
63.
See id.; Goodell, supra note 43.
64.
See Jones, supra note 38.
DEVELOPER,
65.
Machine
Learning
Glossary,
GOOGLE
http://developers.google.com/machine-learning/glossary/?utm_source=googleai&utm_medium=card-image&utm_campaign=training-hub&utm_content=ml-glossary#m
(last visited May 1, 2019).
66.
Goodell, supra note 43.
67.
Id.
68.
Id.
69.
Id.
70.
See id.
71.
See Goodell, supra note 43.
72.
See id.
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perform a scan of a brain. 73 This ML approach is called supervised ML,
which allows computer software to learn by example, either by a photograph
or specific data. 74 This type of learning means the data is classified. 75
On the other hand, an unsupervised ML approach is defined as
“[l]earning without annotated examples, just from experience of data or the
world—trivial for humans but not generally practical for machines.” 76
Unsupervised learning means there are no classified data sets. 77 Using the
example above, in an unsupervised learning approach the algorithm would
not tell the computer how to use MRI controls or even what result it
wanted. 78 Instead, the computer itself would realize there are different
machine controls to be used and different ways to perform an MRI scan and
would try to perform the task on its own. 79 In modern society, the
application of ML is around us every day. 80 The phone app Google Maps
uses supervised ML algorithms to find the quickest route and “calculate
traffic delays based on real-time data.” 81
3.

DL

ML has a lot of mathematical and statistical areas to it. 82 One of
those areas is called DL. 83 DL is defined as a “[ML] technique in which data
is filtered through self-adjusting networks of math loosely inspired by
neurons in the brain.” 84 Those self-adjusting networks are known as
Artificial Neural Networks (“ANNs”) and were originally discovered in 1958
but lost their popularity quickly due to a lack of belief that they would be
very powerful. 85 In 2012, scientists proved that ANNs would be extremely
effective and would fuel large piles of data, thereby giving computers the
ability to perceive new intelligence capabilities. 86 Today, DL is able to
revolutionize the way AI is used by employing neural networks. 87 With the
73.
See id.
74.
See id.; Simonite, supra note 12.
75.
See Goodell, supra note 43; Jones, supra note 38.
76.
Simonite, supra note 12.
77.
See id.; Jones, supra note 38.
78.
See Goodell, supra note 43; Simonite, supra note 12.
79.
See Goodell, supra note 43; Simonite, supra note 12.
80.
Goodell, supra note 43.
81.
Id.
82.
See Simonite, supra note 12.
83.
Id.
84.
Id.
85.
Id.
86.
Id.
87.
Ariel Bleicher, Demystifying the Black Box That Is AI, SCI. AM. (Aug. 9,
2017), http://www.scientificamerican.com/article/demystifying-the-black-box-that-is-ai/.
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use of ANNs, DL is able to put “large data sets through networks set up to
mimic the human brain’s neural network in order to teach computers to solve
specific problems on their own, such as recognizing patterns or identifying . .
. object[s] in a photo[].” 88 The process begins by a neural network first
receiving an input of data—so, for example, pixels of a photograph of a
dog—and scoring this data “according to simple mathematical rules, and
then pass[ing] the [results] to the next layer of [neurons].” 89 A DL network
has “anywhere from three to hundreds of layers.” 90 The last layer in a DL
network outputs a singular prediction—so, for example, it would predict:
This is a photo of a dog. 91 If the last layer makes the incorrect prediction—
for example, this is a photo of a bear—then the algorithm will correct itself
because the neural net has “create[d] a structured set of relationships [during
the process] . . . that can classify new images or perform actions under
conditions it has never encountered before.” 92 The neural networks make it
possible for AI systems to adapt to—and learn with accuracy—patterns that
are too complex and that would take too long for humans to be able to
accomplish on their own. 93 Additionally, these networks reflect the trial and
error process of the human brain, and they do so at a speed that is not
humanly possible. 94
So, what is the difference between regular ML, which involves
supervised and unsupervised learning, and DL? 95 ML forces computers to
perform tasks through the use of repeated drills written in the algorithm; the
computer is constantly being corrected and given instruction by the
programmer—the process is similar to the way a child learns a new word: A
teacher will have the child repeat the word again and again, or perhaps give a
spelling test until that child has learned that new skill. 96 During the process
of ML, the computer does not learn from its mistakes until the programmer
points them out and, until the computer reaches a certain level of accuracy,
88.
Larry Greenemeier, AI Is Not Out to Get Us, SCI. AM. (Oct. 24, 2016),
http://www.scientificamerican.com/article/ai-is-not-out-to-get-us/.
89.
Bleicher, supra note 87.
90.
Id.
91.
Id.
92.
Id.
93.
See id.
94.
Understanding the Black Box of Artificial Intelligence, supra note 48.
95.
Bernard Marr, What Is the Difference Between Deep Learning, Machine
(Dec.
8,
2016,
2:14
AM),
Learning
and
AI?,
FORBES
http://www.forbes.com/sites/bernardmarr/2016/12/08/what-is-the-difference-between-deeplearning-machine-learning-and-ai/#6f4e537226cf.
96.
Abhi Arunachalam, How Deep Is Your Learning?, FORBES (Mar. 29,
2016, 1:13 PM), http://www.forbes.com/sites/valleyvoices/2016/03/29/how-deep-is-yourlearning/.
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the process continues. 97 On the other hand, DL eliminates the need for a
programmer—or teacher—and instead the computer can “self-improve [via]
the [analysis of] large data sets.” 98 With DL, the algorithm is basically
teaching the computer to learn like a human all on its own. 99 Various
companies have already applied the technologies of DL algorithms to their
products. 100 Products that serve as digital assistants, such as Apple’s Siri or
Amazon’s Alexa, are able to recognize speech and translate perfectly
because of neural networks. 101 Machines and computers are able to
recognize images, predict disease, and beat humans at video games because
of deep neural networks. 102 Now, the application of DL to the healthcare
world is making its debut. 103
B.

AI in Medicine

AI is constantly being applied to countless industries—from finance
to transportation—and these algorithms are changing the way we live life. 104
One of the most exciting and hopeful applications of AI to modern industries
is in the context of healthcare. 105 For years, specialists in the field of
healthcare have struggled with balancing the exorbitant amount of patient
information with diagnosing disease accurately, and with an overall shortage
of clinical support. 106 According to the World Health Organization, there is
no indication that there will be a decline in disease, death, or medicine in
general in the future:
[B]y 2020, the prevalence of chronic disease is expected to rise
[fifty-seven percent]. However, advancements in detecting and
diagnosing diseases will help to minimize the cost of treating
chronic diseases. Some of these new technologies include
genomics, proteomics, cell biology, stem cell and organ therapy,
and minimally invasive and robotic surgery. 107

97.
Id.
98.
Id.
99.
Id.
100.
Id.; Goodell, supra note 43.
101.
Bleicher, supra note 87.
102.
Id.
103.
See id.
104.
Ashok, supra note 18.
105.
See id.
106.
See id.; Jennifer Bresnick, Can Healthcare Avoid Black Box Artificial
Intelligence Tools?, HEALTHITANALYTICS.COM: TOOLS & STRATEGIES (Feb. 2, 2018),
http://healthitanalytics.com/news/can-healthcare-avoid-black-box-artificial-intelligence-tools.
107.
Ashok, supra note 18.
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Thankfully, with the implementation of AI in the medical industry,
the way physicians and healthcare professionals handle diagnosing and
treating disease will be approached from an entirely new platform. 108 In
modern society, AI technologies in healthcare are already present in various
medical products such as: Virtual medical devices that can readily diagnose
and track a patient’s health without a doctor present, DL algorithms that can
accelerate and assist in drug development, and the use of robots in
biologicals, genomics, and surgical care. 109 The exponential and doubling
growth of these technologies is why regulatory bodies need to keep a
watchful eye on their outdated polices and the shifting change of how the
medical world is incorporating these devices. 110 Many of the medical
products and devices using AI algorithms today, such as Mobile Health
(“mHealth”) or Deep Patient, are breaching the topic of black-box
medicine—the concern about transparency behind a machine’s thoughts,
such as how and why a machine generates the prediction or diagnosis that it
does. 111
C.

Black-Box Medicine

To put it simply, “black-box medicine [is] the use of opaque
computational models to make decisions related to health care.” 112 The user
or programmer understands what goes in to the computer and the result that
comes out of the computer, but what about the process in between that the
computer performs? 113 That remains a mystery. 114 One of the biggest issues
in applying AI to medicine is trying to figure out why a neural network
makes the decision it does—trying to get to the core behind what happens
between DL layer one and three hundred. 115 The concept of black-box
medicine is not new—for years users have been trusting the results of
technology, apps, and computers without knowing how A gets translated into

108.
Id. Early studies conducted found that nearly $630 million was spent in
the healthcare industry in 2014 on AI technology. Bennett & Habte, supra note 8, at 17. That
number is expected to grow more than nine-fold by the year 2021. Id.
109.
Id.
110.
See id. at 17–18.
111.
W. Nicholson Price II, Regulating Black-Box Medicine, 116 MICH. L.
REV. 421, 429–31 (2017); Bleicher, supra note 87.
112.
W. Nicholson Price II, Black-Box Medicine, 28 HARV. J.L. & TECH. 419,
421 (2015).
113.
Understanding the Black Box of Artificial Intelligence, supra note 48.
114.
See id.
115.
Id.; Bleicher, supra note 87.
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B. 116 The prevalence of black-box medicine is most often seen in clinical
decision making, whether diagnostic or therapeutic, because the computer or
system is most likely providing a particular recommendation to a patient and
will need to be trustworthy—an issue if the software is unable to give its
reasoning as to how it arrived at its recommendation. 117
1.

The Diagnosing Devices of AI

In 2010, IBM built one of the most influential machines in AI
history: Watson. 118 The company’s AI masterpiece shocked the country
with its television debut on Jeopardy!, taking home the grand prize and
defeating two all-time champions. 119 Watson’s “ability to synthesize [large]
quantities of data and produce evidence-based hypotheses” was a unique
characteristic that had never been seen before. 120 By 2012, Watson was
using its data processing abilities to help medical students diagnose and treat
patients. 121 By 2014, Watson had been developed to be used by doctors “to
connect genomic and medical data to help drive more personalized
treatments.” 122 Today, Watson has worked with over twenty cancer
institutes, the Department of Veteran Affairs (“VA”), and is now the
frontrunner to work with the country’s top oncologists to analyze samples of
tumors “look[ing] for mutations in the cancer’s genome.” 123
Watson has worked with over twenty-seven hundred veterans and
will continue to do so through 2019. 124 But how exactly does Watson
work? 125 “Watson [is] powered by DeepQA software,” meaning it is using
116.
Bresnick, supra note 106. The foundation of why a ML or DL computer
does what it does is usually not necessary for the average consumer. See id. This issue and
transparency of black-box medicine is beyond the scope of this Comment.*
117.
Id.
118.
Chung & Zink, supra note 50, at 54. Watson “can read [eight hundred]
million pages a second and can digest the entire corpus of Wikipedia, [and can even read]
decades of law and medical journals.” Goodell, supra note 43.
119.
Chung & Zink, supra note 50, at 54.
120.
See id. at 54–55.
121.
Id. at 54.
122.
Id.
123.
Sarah Wells, IBM Watson Health and the VA Extends Partnership in
(July
19,
2018),
Cancer
Research,
TECHCRUNCH
http://www.techcrunch.com/2018/07/19/ibm-watson-health-and-the-va-extends-partnershipin-cancer-research/.
124.
Id. “[T]he National Cancer Institute . . . estimate[s] [that about] 1,735,350
new cases of cancer will be diagnosed in 2018” and “that the veteran population [is] 3.5
[percent] of the nation’s cancer patients.” Id.
125.
Alison E. Berman, A Look at IBM’s Watson 5 Years After Its Breathtaking
HUB
(Aug.
10,
2016),
Jeopardy
Debut,
SINGULARITY
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an AI software used to analyze, reason, and answer content that is fed into
it. 126 Oncologists use Watson by “[u]pload[ing] the DNA fingerprint of a
patient’s tumor, which indicates which genes are mutated . . . and Watson . . .
sift[s] through thousands of mutations [to] try to identify which [one] is
driving the tumor and therefore what a drug must target.” 127 Unfortunately,
researchers still have kinks to figure out as the United States health system
and its flaws create flaws in the way Watson’s algorithm functions and
processes data—the medical records and information Watson sorts through is
not error free and was “initially digitized for . . . hospital administrators, not
for . . . disease treatment.” 128
But IBM and Watson are not the only dynamic duo making waves in
the world of medical AI; in 2018, Google released a new type of algorithm
that could help predict a patient’s risk of death.129 In May, “[a] woman with
late-stage breast cancer came to a city hospital, fluids already flooding her
lungs. She saw two doctors and [received] a radiology scan. The hospital’s
computers read her vital signs and estimated a 9.3 percent chance she would
die during her stay.” 130 Google applied its new algorithm to Jane Doe to
asses her death risk, something unheard of in healthcare. 131 The result? 132 A
19.9 percent chance, and within just a matter of days, Jane Doe had
passed. 133 Google used Jane Doe’s data to publish research regarding the use
of ANNs and DLs to create a system that would be able to “forecast . . .
patient outcomes, including how long people may stay in hospitals, their
odds of re-admission and chances they will soon die.” 134 The AI system
used everything from a random scribbled nurse’s note hidden deep in Jane’s
file to large CT scans to make its prognosis—and it did so in twice the speed
of a doctor, with almost none of the mistakes. 135 The system amazed
researchers and physicians as it “gobbled up all [the] unruly information

http://www.singularityhub.com/2016/08/10/a-look-at-ibms-watson-5-years-after-itsbreathtaking-jeopardy-debut/.
126.
Id.
127.
Id.
128.
Id.
129.
Mark Bergen, Google Is Training Machines to Predict When a Patient
(June
18,
2018,
5:00
AM),
Will
Die,
BLOOMBERG
http://www.bloomberg.com/news/articles/2018-06-18/google-is-training-machines-to-predictwhen-a-patient-will-die.
130.
Id.
131.
See id.
132.
See id.
133.
Id.
134.
Bergen, supra note 129.
135.
Id.
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[and] then spat out predictions . . . even show[ing] which records led it to
[what] conclusions.” 136
Innovation does not stop there; in 2018, more than three new
medical devices that focused on different types of diagnoses received
attention from the FDA. 137 First, Viz.ai engineered a large vessel occlusion
(“LVO”) Proactive Stroke Pathway (“PSP”). 138 Using DL technology, the
software helps automatically detect and alert on-call physicians that a patient
is having signs of a stroke. 139 Additionally, IDx LLC released its new device
IDx-DR which is engineered to detect a condition known as diabetic
retinopathy, exclusively found in adults with diabetes. 140 Moreover, AI
developers have started to utilize algorithms similar to Watson’s, that allow
software to make a diagnosis by reviewing images stored in a database. 141
The impact of software such as IBM’s Watson, and Google’s
Medical Brain on regulatory bodies are countless. 142 Such black-box
applications of ML and DL algorithms to provide for “medication assistance
. . . and communicat[ion] with doctors” create access to data and the ability
136.
137.

Id.
Rabiya S. Tuma, Caution Needed with Artificial Intelligence in Medicine,
(May
29,
2018),
Experts
Warn,
MEDSCAPE
http://www.medscape.com/viewarticle/897350#vp_1; see also Gin & Helwig, supra note 22.
In 2016, an “experimental neural net . . . called Deep Patient” was created to review over
“[twelve] years’ worth of electronic health records—including [everything from] test results
[to] hospital visits—from 700,000 patients.” Bleicher, supra note 87. The system was
successful and able to predict accurate diagnosis on its own without the help or input from a
doctor. Id. This system is a traditional black-box medical AI, as researchers know what goes
in and understand the result that comes out, but do not receive an analysis or reasoning behind
the diagnosis given. Id.
138.
Gin & Helwig, supra note 22; Tuma, supra note 137; Viz.ai, VIZ. AI,
http://www.viz.ai[http://www.web.archive.org/web/20181109145100/https://www.viz.ai/]
(last visited May 1, 2019).
139.
Gin & Helwig, supra note 22; Viz. ai, supra note 138.
140.
Gin & Helwig, supra note 22; see also Tuma, supra note 137.
141.
See Kif Leswing, Apple CEO Tim Cook Gave a Shout-Out to a $100-PerYear App for Doctors — Here’s What It Does, BUS. INSIDER (Nov. 19, 2017, 8:30 AM),
http://www.businessinsider.com/visualdx-machine-learning-app-for-skin-diagnosis-ceointerview-2017-11.
142.
See Drew Simshaw et al., Regulating Healthcare Robots: Maximizing
Opportunities While Minimizing Risks, 22 RICH. J.L. & TECH., no. 2, 2016, at 1, 15. Predicting
medical events before they occur is also a very big benefit of AI’s application to health. See
Abby Norman, Your Future Doctor May Not Be Human. This Is the Rise of AI in Medicine.,
FUTURISM: SCI-FI VISIONS (Jan. 31, 2018), http://futurism.com/ai-medicine-doctor/. Recent
studies indicate that with “data from 378,256 patients, a self-taught AI [was able to predict]
7.6 percent more cardiovascular events in patients than the [previous] standard of care.” Id.
To put it in layman’s terms, the AI “had 1.6 percent [less] . . . cases in which [a] risk was
overestimated, possibly leading to patients having unnecessary, [risky] procedures or
treatments [done].” Id.
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to share such data on a global scale. 143 These applications and data
collections are very distinguishable from what is already being utilized in the
healthcare world, such as websites like WebMD and the like, creating a
regulatory loophole in classification categories that fall under the jurisdiction
of regulatory bodies such as the FDA. 144
2.

Surgical Robots

For nearly a decade, the idea of going [u]nder the [r]obotic [k]nife
has been making headlines. 145 Infamous AI robot systems, like the daVinci
Surgical System, provide doctors with a robotic arm of a sort, turning
surgery into a robotic video game. 146 The daVinci system allows surgeons to
change how operations are performed by allowing them to make a few small
incisions. 147 While surgical robots “present a number of . . . legal issues
[such as] . . . product and practice liability,” they also apply ML and DL AI
in traditional medical devices providing for unique regulation challenges. 148
The daVinci is not the only robodoc; in 2010, Canadian surgeons used
daVinci in-tandem with the world’s first robot anesthesiologist, McSleepy,
to perform surgery successfully. 149 The evolution of robotic surgeons does
not necessarily mean a green light for the AI application to the medical
device world; the FDA needs to be on the look-out. 150 A study conducted in
2015 by MIT staff using FDA data of robotic surgery statistics discovered
that “144 patient[s] [had died] and 1,391 patient injuries [had been] reported
[due to] technical difficulties or device malfunctions.” 151 The study showed
that the more complex the surgery, the higher the number of events
occurred. 152 The question to consider becomes: As AI begins to be applied
to accountable areas of life such as medicine and surgery, who begins to
regulate it and how? 153

143.
See Simshaw et al., supra note 142, at 11.
144.
See id. at 15, 17–20.
145.
Norman, supra note 142.
146.
See id.; Simshaw et al., supra note 142, at 9.
147.
Hamet & Tremblay, supra note 16, at S37; Anthea Gerrie, The da Vinci
Code: Why a Robotic System Replaces Chopstick Surgery, MEDTECH ENGINE: INNOVATION &
ENTREPRENEURSHIP (Oct. 14, 2016), http://www.medtechengine.com/article/da-vinci-surgicalsystem/.
148.
Simshaw et al., supra note 142, at 9.
149.
Norman, supra note 142.
150.
See id.
151.
Id.
152.
Id.
153.
See Simshaw et al., supra note 142, at 7, 15, 17–20.
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Precision Medicine and Drug Discovery

As the role of AI continues to be applied to various areas of the
medical world, one of the biggest applications is in the one-size-fits-all
treatment mentality that has plagued the healthcare industry. 154 Thanks to
these technologies, we are now aware that everyone has a different genetic
code and when it comes to disease treatment and prevention, may react
differently to medications. 155 Precision medicine is the emerging approach
for drug treatment, taking into account the varying genetic codes and
disregarding the one-size-fits-all approach. 156 The National Institute of
Health defines precision medicine as “an emerging approach for disease
treatment and prevention that takes into account individual variability in
genes, environment, and lifestyle.” 157 This type of treatment would break the
barriers of illness, allowing people to recover faster and stay healthy
longer. 158 How do we accomplish the wonders of precision medicine? 159
Well, due to the length of time it takes to develop a drug and the extremely
high cost, not to mention the amount of data, AI, ML, and DL algorithms can
help to resolve many of the issues that are present when it comes to treating
diseases such as Ebola and cancer. 160 In 2015, a company called Atomwise
released its software—a database that runs off of DL and AI—to help reengineer existing medications that could help treat the Ebola virus. 161 The
DL black-box system was successful in identifying two medications that
would help reduce the pain and suffering that people with the virus
experience—a process that usually takes ten months to ten years to
uncover. 162 But the drug innovation does not stop there; in May of 2018,
researchers at the University of Washington School of Medicine developed a
154.
Hema Chamraj, Powering Precision Medicine With Artificial Intelligence,
INTEL AI (Mar. 6, 2018), http://ai.intel.com/powering-precision-medicine-artificialintelligence/; see also There Is No Precision Medicine Without Artificial Intelligence, MED.
FUTURIST (Oct. 19, 2017), http://medicalfuturist.com/no-precision-medicine-without-artificialintelligence/.
155.
See Chamraj, supra note 154; There Is No Precision Medicine Without
Artificial Intelligence, supra note 154.
156.
Chamraj, supra note 154.
157.
Id.
158.
Id.
159.
See id.; There Is No Precision Medicine Without Artificial Intelligence,
supra note 154.
160.
See Ashok, supra note 18; Chamraj, supra note 154; There Is No
Precision Medicine Without Artificial Intelligence, supra note 154.
161.
There Is No Precision Medicine Without Artificial Intelligence, supra note
154; see also Marr, supra note 95.
162.
There Is No Precision Medicine Without Artificial Intelligence, supra note
154.
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way to use mini robots to fight kidney disease. 163 Through the use of liquidhandling robots researchers have changed the growth of stem cells to
produce more complex three-dimensional structures that are able to mimic
“mutations that cause polycystic kidney disease.” 164 Researchers and
innovators in the drug development world call this and other applications of
AI a “secret weapon in our fight against disease.” 165
4.

mHealth

mHealth is commonly known as a type of AI medicine that uses
“mobile communications devices [such as] smartphones [or tablets] for
health or medical purposes, usually for diagnosis, treatment, or . . . wellbeing and maintenance.” 166 When it comes to mHealth apps that provide
maintenance or guidance on how to stay healthy, think of the FitBit, the
Apple Watch, and other devices that track steps and monitor heart rates. 167
Such devices have already been given regulatory review by the FDA and, as
such, this Comment is focused on mHealth apps that are focused on
predicting diagnosis and providing diagnosis, treatment, or other important
information that would usually be administered by a physician. 168 An
example of such an app is VisualDx. 169 A mobile app “targeted at trained
and credentialed doctors who . . . use it to help diagnose skin conditions and
disorders.” 170 Dr. James Shoemaker, a doctor with Elkhart Emergency
Physicians in Elkhart, Indiana, is an avid user of VisualDx and often uses it
with his patients. 171 Shoemaker was able to even diagnose a young child
with a very rare disorder called Stevens-Johnson syndrome, remarking that
he “had an idea it [was] that” and that “[t]he program reinforced [his]
diagnosis and helped [him] figure out the next step.” 172 The app uses an AI
program called CoreML, which allows it to use an ML algorithm on a phone
and—this is the exciting part—instead of having to process photos on a
163.
Robots Grow Mini-Organs from Human Stem Cells, SCIENCEDAILY (May
17, 2018), http://www.sciencedaily.com/releases/2018/05/180517123300.htm.
164.
Id.
165.
Id.
166.
Price II, supra note 111, at 428 (quoting Nathan Cortez, The Mobile
Health Revolution?, 47 U.C. DAVIS L. REV. 1173, 1176 (2014)).
167.
See id. at 428–29.
168.
Id.; see also infra Part I–V.
169.
Leswing, supra note 141.
170.
Id.
171.
Arlene Weintraub, Hospitals Utilize Artificial Intelligence to Treat
Patients, U.S. NEWS & WORLD REP.: CIVIC (Oct. 31, 2017, 11:00 AM),
http://www.usnews.com/news/healthcare-of-tomorrow/articles/2017-10-31/hospitals-utilizeartificial-intelligence-to-treat-patients.
172.
Id.
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server, the algorithm can readily process it on a handheld device. 173 What
exactly does this mean? 174 It means that VisualDx allows physicians to scan
a portion of a patient’s body, rather than taking a photo that is saved and
uploaded, and the neural network is trained by a “library of professional
medical images” to provide doctors with a search of “symptoms, signs, and
other patient factors” and then “confirm and validate [a] diagnos[i]s.” 175
III.

THE FDA: AN OVERVIEW

“[T]he upheavals [of AI] can escalate quickly and become scarier
and even cataclysmic. Imagine how a medical robot, originally programmed
to rid cancer, could conclude that the best way to obliterate cancer is to
exterminate humans who are genetically prone to the disease.”176
Established in 1906, the FDA is the regulatory authority over the
majority of food, drugs, and medical products that the public consumes on a
daily basis. 177 As such, the FDA is charged with the responsibility of
regulating all drugs and medical devices that implement AI technologies. 178
Since its establishment, the FDA has had to respond to numerous changes in
the field of healthcare and it is vital to briefly review such changes within the
FDA’s regulatory framework before discussing the FDA’s current AI
framework. 179
A.

Historical Overview of the FDA’s Regulatory Framework

In 1906, the Federal Food and Drugs Act was signed into law,
creating what is known today as the FDA. 180 Upon the initial passage of the
Act, the FDA’s regulatory powers were limited to regulating drugs that were
unsanitary or unsafe. 181 The FDA’s effectiveness in regulating therapeutic
drugs before they hit the mass markets was a problem for Congress, as well

at E2.

173.
174.
175.
176.

Leswing, supra note 141.
See id.
Id.
Nick Bilton, Artificial Intelligence as a Threat, N.Y. TIMES, Nov. 6, 2014,

177.
RONALD HAMOWY, MEDICAL DISASTERS AND THE GROWTH OF THE FDA 3
(2010), http://www.independent.org/pdf/policy_reports/2010-02-10-fda.pdf; Merrill, supra
note 17, at 1758.
178.
Merrill, supra note 17, at 1753, 1753.
179.
See HAMOWY, supra note 177, at 5.
180.
Merrill, supra note 17, at 1758; see also Act of June 30, 1906, ch. 3915,
34 Stat. 768. Before 1927, the FDA was known as the Division of Chemistry and did not get
the name FDA until June 1940. John P. Swann, FDA’s Origin, FDA (Feb. 1, 2018),
http://www.fda.gov/AboutFDA/History/FOrgsHistory/EvolvingPowers/ucm124403.htm.
181.
Merrill, supra note 17, at 1802.
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as the consumer, because the FDA did not have the regulatory scope to
premarket review every drug or medical device. 182 Instead, the regulatory
process that the FDA did have placed all the standards of review on the
product, food, or device instead of on the manufacturers themselves; this
created large loopholes for the FDA. 183
In 1937, the FDA’s lack of regulatory authority became a public
health crisis after an administration of elixir sulfanilamide led to the death of
over one hundred people, many of them children. 184 The public health crisis
prompted Congress to pass the Federal Food, Drug, and Cosmetic Act
(“FDCA”), enabling the requirement of premarket approval. 185 The process
for a manufacturer to market a drug changed drastically with the FDCA as it
required manufacturers to contact the FDA within a span of one hundred
eighty days before placing a drug out on the market; if no challenge or
question was raised with regard to safety concerns by the FDA, then the
manufacturer would be allowed to sell its drug to the public. 186 When
drafting the FDCA, Congress made sure to consider all “exotic mechanical
and electrical devices” that would fall under the scope of the definition of
drug. 187 Such considerations took evidence when Congress “expanded the
definition of drug to include devices,” making an effort to expand the FDA’s
regulatory scope to device-like products—subjecting them to premarket
approval—without having to create a secondary regulatory category. 188 At
the time, standard devices such as wheelchairs, leg braces, and surgical nails
posed no danger to patients. 189 However, it was shortly after the passing of
the FDCA that a new wave of technologies, with much more sophisticated
designs, began to advance the medical world. 190
The new wave of technological innovation following the FDCA
created a severe lack of regulatory authority for the FDA. 191 The FDA was
unable to premarket approve medical devices that were not considered nor
provided for under the FDCA’s original or expanded definition of a drug. 192
182.
Id. at 1761, 1802.
183.
Id. at 1761–62.
184.
Id. at 1761; HAMOWY, supra note 177, at 6.
185.
Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717 § 505, 52 Stat.
1040, 1052 (1938) (codified at 21 U.S.C. § 301 (2012)); Merrill, supra note 17, at 1764–65.
186.
Drug Amendments of 1962, Pub. L. 87–781, § 104, 76 Stat. 780 (codified
as amended at 21 U.S.C. § 301 (2012)); Merrill, supra note 17, at 1764–65.
187.
Merrill, supra note 17, at 1765, 1801–02; HAMOWY, supra note 177, at 9;
see also Federal Food, Drug, and Cosmetic Act, § 201(g), at 1041.
188.
Merrill, supra note 17, at 1802.
189.
Id. at 1803.
190.
Id.; see also Federal Food, Drug, and Cosmetic Act, § 1, at 1040.
191.
Merrill, supra note 17, at 1803–04; see also Federal Food, Drug, and
Cosmetic Act, § 1, at 1040.
192.
See Merrill, supra note 17, at 1804.
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Over time, larger and larger loopholes formed in the FDA’s regulatory
process, as medical devices and drugs that the FDA attempted to declare new
drugs, fell out of regulatory reach and hit the market before the FDA
approved them as safe and effective. 193
In 1960, Congress was faced with another mass health crisis when
numerous infants were born with severe birth defects due to the ingestion of
thalidomide, a drug given to pregnant woman for nausea. 194 Congress and
the FDA realized it was time to amend the FDCA when costly and disruptive
recalls of medical devices, such as intrauterine devices (“IUDs”) and
antibiotics, plagued the country due to an outdated regulatory scheme being
applied to the growing technological advances in the medical field. 195 The
Medical Device Amendments (“the Amendments”) of 1976 expanded the
scope of the FDA and transformed the regulatory scheme of the FDA’s
authority into one of the most complicated and conservative drug regulation
systems in the world. 196 The FDA had now been given the ability to issue
guidance on manufacturing standards for medical devices, to ban dangerous
products that had already been on the market, and to require premarket
notification of such defective products. 197 The Amendments also established
the fundamental frameworks of the regulatory process that the FDA uses
today: Classification, levels of control, and premarket notification. 198 While
the FDCA gave the FDA the authority to regulate medical devices for the
first time, the Amendments established the FDA’s authority to require
manufacturers of any medical device to prove its safety and effectiveness
before selling it to the public. 199
B.

Regulating Drugs and Devices

The FDA is arranged into multiple centers that focus on regulating
specific areas of products: the Center for Food Safety and Applied Nutrition
(“CFSAN”); the Center for Drug Evaluation and Research (“CDER”); the
Center for Biologics Evaluation and Research (“CBER”); and the Center for

193.
See id. at 1805–06.
194.
HAMOWY, supra note 177, at 11; Merrill, supra note 17, at 1764 & n.35.
195.
See Merrill, supra note 17, at 1805–06.
196.
See id. at 1808; Medical Device Amendments of 1976, Pub. L. No. 94295, 90 Stat. 539.
197.
Merrill, supra note 17, at 1808.
198.
Id. at 1809–10; Medical Device Amendments of 1976, §§ 85 1-2.
199.
See Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, § 505, 52
Stat. 1040, 1052 (1938) (codified at 21 U.S.C. §§ 301 (2012)); Merrill, supra note 17, at 1765,
1776, 1800.
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Devices and Radiological Health (“CDRH”).200 The centers primarily
responsible for regulating drugs, medical devices and biopharma are CDER,
CBER, and CDRH. 201
1.

CDER

CDER is charged with regulating “over-the-counter and prescription
drugs, including biological therapeutics and generic drugs.” 202 If a
pharmaceutical company or drug manufacturer wants to market a new drug,
it must abide by the regulations set out by CDER. 203 The multi-step process
for manufacturing and selling a new drug is exhaustive and costly. 204 First,
the manufacturer has to file an Investigational New Drug (“IND”)
application—which is based on test results from initial experiments
conducted on animals—to get approval for research to experiment the drug
on human subjects. 205 If the applicant is approved, then he or she can begin
human clinical trials and attempt to test the safety and efficacy of the drug. 206
The purpose of this step is to gather evidence that the new drug meets the
FDA’s requirements for marketing approval. 207 The process of clinical
human trials is lengthy, consisting of three phases. 208 Phase I studies focus
on gathering test data regarding the safety of the drug and typically involve
twenty to eighty human subjects; Phase II focuses on the effectiveness of the
drug and involves several dozen to three hundred people; and Phase III

200.
John Miller, Beyond Biotechnology: FDA Regulation of Nanomedicine,
COLUM. SCI. & TECH. L. REV., 2003, at 1, 13; see also About CBER, FDA,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/u
cm123340.htm (last updated Feb. 6, 2018); How Drugs Are Developed and Approved, FDA,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApprov
ed/default.htm (last visited May 1, 2019); Overview of CDRH Transparency, FDA,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/
CDRHTransparency/ucm199624.htm (last updated Sept. 14, 2018).
201.
Miller, supra note 200, at 13; see also About CBER, supra note 200; How
Drugs Are Developed and Approved, supra note 200; Overview of CDRH Transparency,
supra note 200.
202.
About the Center for Drug Evaluation and Research, FDA,
http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/
(last
updated Feb. 27, 2019).
203.
See How Drugs Are Developed and Approved, supra note 200.
204.
See The FDA’s Drug Review Process: Ensuring Drugs Are Safe and
Effective, FDA, http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm (last
updated Nov. 24, 2017).
205.
Id.
206.
Id.
207.
Id.
208.
Id.
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focuses on specific treatment variables and involves anywhere from a few
hundred to three thousand people. 209
“The goal [of these phases] is to determine what the drug’s most
frequent side effects are and, often, how the drug is metabolized and
excreted.” 210 The length of each phase can vary greatly; for example, Phase
II trials can vary anywhere from “[s]everal months to [two] years.” 211 At this
stage, “[a]pproximately [thirty-three percent] of drugs [are approved to]
move to the next phase.” 212 If there is evidence of effectiveness, Phase III
studies begin with the purpose of “demonstrat[ing] whether or not a product
offers a treatment benefit to a specific population . . . [and] these studies
involve [three hundred] to [three thousand] participants.” 213 The length of
Phase III trials can vary anywhere from one to four years.214 According to
the FDA: “Phase [III] studies provide most of the safety data. In [Phase I
and II] studies, it is possible that less common side effects might have gone
undetected. Because [the Phase III] studies are larger and longer in duration,
the results are more likely to show long-term or rare side effects.” 215
Once the IND clinical trials are completed, CDER requires that postmarket studies be completed; these are at times referred to as Phase IV
trials. 216 Phase IV trials involve several thousand volunteers and involve the
gathering of data on the drug “after the FDA has approved [the] product for
marketing.” 217 After the IND phase is complete, the drug manufacturer
applies for a New Drug Application (“NDA”) and submits along with it all
the animal and human experimental data, proposed labeling, and chemical
makeup of the drug. 218 At this stage, CDER reviews all the data and, after
evaluating the data from the clinical trials, weighs whether the product’s
benefits outweigh its risks to decipher whether to approve or deny the
drug. 219 CDER’s surveillance is never quite finished when it comes to a

209.
The FDA’s Drug Review Process: Ensuring Drugs Are Safe and
Effective, supra note 204.
210.
Id.
211.
Step
3:
Clinical
Research,
FDA,
http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm (last updated Jan. 4, 2018).
212.
Id.
213.
Id.
214.
Id.
215.
Id.
216.
Step 3: Clinical Research, supra note 211.
217.
The FDA’s Drug Review Process: Ensuring Drugs Are Safe and
Effective, supra note 204; Step 3: Clinical Research, supra note 211.
218.
How Drugs Are Developed and Approved, supra note 200; The FDA’s
Drug Review Process: Ensuring Drugs Are Safe and Effective, supra note 204.
219.
See How Drugs Are Developed and Approved, supra note 200.

Published by NSUWorks, 2019

23

Nova Law Review, Vol. 43, Iss. 3 [2019], Art. 6

410

NOVA LAW REVIEW

[Vol. 43

drug’s development of efficacy and safety. 220 “[I]t is impossible to have [all
the] information about the safety of a drug at the time of approval.” 221 Thus,
CDER and the FDA are constantly reviewing drugs post-market for safety. 222
2.

CDRH

The FDA center responsible for regulating medical devices is the
CDRH. 223 The process for classifying a medical device is significantly
easier and less restrictive than the drug approval process. 224 A medical
device is defined as:
[A]n instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article,
including [any] component part, or accessory which is . . . intended
for use in the diagnosis of disease or other conditions, or in the
cure, mitigation, treatment, or prevention of disease, in man or
other animals, or intended to affect the structure or any function of
the body of man or other animals, and which does not achieve its
primary intended purposes through chemical action within or on
the body of man or other animals. 225

Medical devices are regulated using a risk-based classification
system. 226 Using this approach, all devices could fall under FDA regulation,
which would entail “registration, listing, and . . . reporting requirements.” 227
The higher the risk, the higher the class: Class I—simple low-risk devices;
220.
See id.; About the Center for Drug Evaluation and Research, supra note
202;
Step
5:
FDA
Post-Market
Drug
Safety
Monitoring,
FDA,
http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405579.htm (last updated Jan. 4, 2018).
221.
Step 5: FDA Post-Market Drug Safety Monitoring, supra note 220.
222.
See The FDA’s Drug Review Process: Ensuring Drugs Are Safe and
Effective, supra note 204. With regard to right-to-try laws, this falls beyond the scope of this
Comment and will not be discussed. See Jacqueline Howard, What You Need to Know About
HEALTH
(May
29,
2018,
1:50
PM),
Right-to-Try
Legislation,
CNN:
http://www.cnn.com/2018/03/22/health/federal-right-to-try-explainer/index.html.
223.
Overview
of
Device
Regulation,
FDA,
http://www.fda.gov/medicaldevices/deviceregulationandguidance/overview/default.htm (last
updated Aug. 31, 2018).
224.
See
Is
the
Product
a
Medical
Device?,
FDA,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYour
Device/ucm051512.htm (last updated Mar. 22, 2018); The FDA’s Drug Review Process:
Ensuring Drugs Are Safe and Effective, supra note 204.
225.
21 U.S.C. § 321(h) (2012); Is the Product a Medical Device?, supra note
224.
226.
Price II, supra note 111, at 438.
227.
Id.
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Class II—medium risk devices; or Class III—high risk devices. 228 These
categories are determined based upon the risks such devices may pose and
the regulatory controls that will need to be provided to assure safety and
effectiveness. 229 “Class I devices . . . pose the lowest risk to [a] patient . . .
Class III devices pose the highest risk.” 230 The controls that a class is subject
to is based upon the regulatory measures necessary to ensure safety and
efficacy. 231 In addition to a three-tiered classification system, the CDRH
employs varying levels of review that must be met before allowing a device
to enter the market. 232 A new device may be subject to either a total
exemption or a 510(k) premarket notification process if the device is subject
to a Class I or II classification or, if the device falls under Class III, a
premarket approval process (“PMA”). 233 Generally, the largest area of
regulation for medical devices rests with the category of Class III medical
devices. 234 Any device manufactured after 1976 is defaulted into Class III
228.
Id.
229.
See 21 U.S.C. § 360c(a)(1) (2012).
230.
Overview of Medical Device Classification and Reclassification, FDA,
http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cdrh/cdrhtran
sparency/ucm378714.htm (last visited May 1, 2019). Class I devices are subject to general
controls, Class II are subject to special controls, and only Class III devices are subject to
complete review for safety and effectiveness. 21 U.S.C. § 360c(a)(1); Premarket Approval
(PMA),
FDA,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevic
e/PremarketSubmissions/PremarketApprovalPMA/default.htm (last visited May 1, 2019); see
also
Regulatory
Controls,
FDA,
http://www.fda.gov/medicaldevices/deviceregulationandguidance/overview/generalandspecial
controls/default.htm (last updated Mar. 27, 2018).
231.
See 21 U.S.C. § 360c(a). An example of a Class I product is an elastic
bandage. What’s My FDA Medical Device Classification, CORTEX DESIGN INC.: IDEAS (June
25, 2018), http://www.cortex-design.com/blog/whats-my-fda-medical-device-classification/.
An example of a Class II product is an infusion pump. Id. An example of a Class III product
is a cochlear implant. Id.
232.
Spenser F. Powell, Changing Our Minds: Reforming the FDA Medical
Device Reclassification Process, 73 FOOD & DRUG L.J. 177, 184 (2018).
233.
Id. at 184–85; Premarket Approval (PMA), supra note 230.
234.
See Premarket Approval (PMA), supra note 230. In 1997, the FDA
Modernization Act was passed and it allowed for the exemption of the majority of Class I
devices from 510(k) premarket notification on the condition that “the device is not ‘intended
for a use which is of substantial importance in preventing impairment of human health’ and
does not ‘present[] a potential unreasonable risk of illness or injury.’” Powell, supra note 232,
at 185 (quoting Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105115, § 206(a), 111 Stat. 2296, 2339 (codified as amended at 21 U.S.C. § 301 (2012))). In
2012, the FDA Safety and Innovation Act further expedited the process of medical device
approval, giving the FDA “the authority to alter device classification [via] administrative
order rather than regulation.” Powell, supra note 232, at 185 (quoting Jeffrey K. Shapiro,
Substantial Equivalence Premarket Review: The Right Approach for Most Medical Devices,
69 FOOD & DRUG L.J. 365, 367 n.3677 (2014)); see also Food and Drug Administration Safety
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and subject to a PMA, unless the CDRH finds that, either there is a
substantially equivalent device on the market classified as I or II and grants
510(k) approval—this acts as a loophole to having a Class III device being
regulated as such—or that based upon a de novo determination by the FDA
the statutory definition of Class I or II is met. 235
3.

CBER

CBER regulates a broad area of concern in public health. 236 This is
the regulation of biological related products called biologics, including
anything from blood, vaccines, tissues, and gene therapies—many of which
are created using biotechnology. 237 The FDA opines that “[t]hese products
often represent cutting-edge biomedical research and, in time, may offer the
most effective means to treat a variety of medical illnesses and conditions
that presently have few or no other treatment options.” 238 The process for a
manufacturer to obtain approval for either clinical testing or license to
market a new biological product is similar to the process under CDER’s
purview. 239 CBER is responsible for determining that a product is “safe,
pure, potent, and manufactured accordingly.” 240
C.

The 21st Century Cures Act

In 2016, the 21st Century Cures Act (“the Cures Act”) was enacted
by Congress. 241 The Cures Act was enacted with various purposes in mind,
but one of the key factors was the clarification of “the FDA’s regulatory
authority over digital health and medical devices.” 242 More specifically, one
aspect of the Act titled Clarifying Medical Software Regulation clarified
what medical software does and does not fall under the purview of the
and Innovation Act, Pub. L. No. 112-144, § 101, 126 Stat. 993, 996 (2012) (codified as
amended at 21 U.S.C. § 301 (2012)).
235.
See 21 U.S.C. § 360c(f)(2)-(3); Premarket Approval (PMA), supra note
230.
236.
See About CBER, supra note 200.
237.
Id.
238.
Id.
239.
Miller, supra note 200, at 15.
240.
Id. (quoting 1 JAMES T. O’REILLY, HISTORY LEADING TO THE BIOLOGICS
PRICE COMPETITION AND INNOVATION ACT OF 2009 § 13:156, Westlaw (database updated June
2018).
241.
Bennett & Habte, supra note 8, at 18; see also 21st Century Cures Act,
Pub. L. No 114-255, § 1, 130 Stat. 1033, 1033 (2016).
242.
Bennett & Habte, supra note 8, at 18; see also 21st Century Cures Act, §
1, 130 Stat. at 1033.
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FDA. 243 Pursuant to the Act, digital health—under purview of the FDA and
subject to regulatory authority—includes machines or devices that use AI
algorithms such as ML or DL “to provide diagnostic information for
patients.” 244 The Cures Act completely changed the way the FDA regulated
medical devices, including the way mobile devices are incorporated into the
definition of both digital devices and medical devices. 245 Most importantly,
the Cures Act allowed for the provision that Class III devices be regulated or
excluded from regulation as Class I or Class II devices, given they are lowrisk medical software that “serve as electronic patient records, assist in
displaying or storing data, or provide limited clinical decision support.” 246
To put it simply, if the algorithm does not provide a diagnosis or predict a
course of treatment, then the FDA does not regulate it. 247 Until modern
society began utilizing Fitbits, Apple Watches, and other mobile devices to
track steps taken, monitor their hearts, and for other health reasons, a medical
device was traditionally thought of and used only to provide measurements
or give treatments. 248 Given the increasing amount of entities using and
implementing the amount of AI software or support, and the imperfect fit
between AI and healthcare, the FDA provided a pilot program to pre-certify
eligible digital health developers who could market their devices without
additional FDA review. 249
IV.

REGULATING DR. ROBOT

The pace of progress in [AI]—I’m not referring to narrow AI—is
incredibly fast. Unless you have direct exposure to groups like
Deepmind, you have no idea how fast—it is growing at a pace

243.
Price II, supra note 111, at 439–40 (citing to 21st Century Cures Act §
3060, 130 Stat. at 1130).
244.
Bennett & Habte, supra note 8, at 18; see also 21st Century Cures Act, §
3051, 130 Stat. at 1121.
245.
See Price II, supra note 111, at 439–40; see also 21st Century Cures Act,
§ 515c, 130 Stat. at 1121. The Cures Act attempts to streamline and address some of the
issues the FDA has already faced in seeking to clarify software device and non-software
device involved in diagnosing and treating diseases. Price II, supra note 111, at 439–40.
However, the Cures Act does not specifically address all AI technology. See 21st Century
Cures Act, § 515c, 130 Stat. at 1121–24.
246.
Bennett & Habte, supra note 8, at 18; see also Price II, supra note 111, at
438.
247.
Bennett & Habte, supra note 8, at 18; see also 21st Century Cures Act, §
515c, 130 Stat. at 1121–24.
248.
See Bambauer, supra note 11, at 386.
249.
Bennett & Habte, supra note 8, at 18.
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close to exponential. The risk of something seriously dangerous
happening is in the five-year time frame. [Ten] years at most. 250

A.

The FDA’s Digital Health Innovation Action Plan

In 2018, the FDA released a potential remedy to the AI loophole in
its regulatory policies. 251 The Digital Health Software Precertification
Program (“Pre-Cert”) was created by the FDA to potentially regulate certain
software that abides by FDA medical device standards to “qualify for either
an exemption from premarket review for lower risk . . . products, or [for] a
faster review of higher risk products.” 252 The main difference between PreCert and the Cures Act? 253 “Pre-Cert focuse[s] on free-standing software . . .
apps designed to diagnose or treat disease.” 254 The program is designed to
speed up regulatory review for companies that have exhibited quality
medical devices and drugs, as well as in software development. 255 Pre-Cert
works by using five working models based on principles that will be used to
evaluate devices that manufacturers submit for Pre-Cert. 256 The principles
are: “(i) product quality, (ii) patient safety, (iii) clinical responsibility, (iv)
cybersecurity protection, and (v) proactive culture.” 257 The FDA uses these
principles to evaluate and monitor the AI algorithm which a medical device
uses. 258 The main goal of this program is to look at the developer of the
software instead of targeting the product itself, as the FDA has done in years
prior. 259 It is important to note that the Pre-Cert program is not law, and
FDA guidance still creates a loophole for manufacturers that are creating
250.
Marr, supra note 29.
251.
FDA Releases Software Precertification Working Model, JONES DAY
(May 30, 2018), http://www.jdsupra.com/legalnews/fda-releases-software-precertification65942/.
252.
Id.; see also Theodore T. Lee & Aaron S. Kesselheim, U.S. Food and
Drug Administration Precertification Pilot Program for Digital Health Software: Weighing
the Benefits and Risks, 168 ANNALS INTERNAL MED. 730, 730–31 (2018).
253.
Compare Lee & Kesselheim, supra note 252, at 731, with 21st Century
Cures Act, Pub. L. No. 114-255, § 1, 130 Stat. 1033, 1033 (2016).
254.
Experts Express Concerns About FDA Precertification Program for
Health Apps, HEALIO (Apr. 10, 2018), http://www.healio.com/internal-medicine/practicemanagement/news/online/%7B30f0ee35-f2e2-408f-a35a-723df18a9217%7D/experts-expressconcerns-about-fda-precertification-program-for-health-apps.
255.
Lee & Kesselheim, supra note 253, at 730; FDA Releases Software
Precertification Working Model, supra note 251.
256.
FDA Releases Software Precertification Working Model, supra note 251.
257.
Id.
258.
See id.; Gin & Helwig, supra note 22.
259.
See FDA Releases Software Precertification Working Model, supra note
251.
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helpful medical devices and drugs for the time being. 260 For now, until such
guidance is adopted as law by Congress, developers can still seek
classification of their medical device through the FDA’s 510(k) process or
wait it out if their device is a Class III device. 261
Nine companies were selected by the FDA to participate in a pilot
program of the Pre-Cert process. 262 The companies—Apple, Samsung,
Verily, Johnson & Johnson, Roche, and Fitbit, among them—were all named
companies selected to participate and, as such, are now required to share
information such as quality management and post-market data, and to allow
FDA visitation to corporate sites. 263 The Pre-Cert program may be “an
encouraging move on the FDA’s part, [but there are] some . . . raising
concerns that it will pose more risks to consumers by allowing them to
purchase products before there are evidence-based results”—one of the few
risks of regulating Dr. Robot. 264
B.

The Risks of Regulating Dr. Robot

Apple Watches are telling us our heart rates, Fitbits are telling us
how many steps we walk, and mobile apps are telling us to drink more
water. 265 All of these technologies are possible because of AI algorithms—
algorithms that are even making medication smarter. 266 But “innovation
moves fast—much faster than” regulation—and patients look to regulators to
protect them from the dangers that devices and drugs can potentially pose. 267
The biggest risk of regulating robots in health comes with the speed in which

731.
731.

260.

See Gin & Helwig, supra note 22; Lee & Kesselheim, supra note 253, at

261.

See Gin & Helwig, supra note 22; Lee & Kesselheim, supra note 253, at

262.
FDA Selects Participants for New Digital Health Software
Precertification Pilot Program, FDA: NEWS RELEASE (Sept. 26, 2017)
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm577480.htm.
263.
Id.
264.
Shireen Yates, A Digital Health Revolution Is Happening Now, but the
(Mar.
8,
2018,
9:19
AM),
FDA
Can’t
Keep
Up,
OBSERVER
http://www.observer.com/2018/03/digital-health-revolution-happening-now-fda-cant-keepup/.
265.
Marshall, supra note 7; Molteni, supra note 10; Hint Water, 10 of the Best
Water Apps to Use for Free, QUENCH (June 21, 2016), http://www.thequench.com/water/8-ofthe-best-water-apps-to-use-for-free/.
266.
Chamraj, supra note 154; see also Bambauer, supra note 11, at 391–92.
267.
Yates, supra note 264; see also Tuma, supra note 137.
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the FDA either wants to or cannot regulate these devices and drugs such as,
for example, the home genomics kit 23andMe. 268
Initially, the home genomics kit, utilizing AI, escaped regulation
because it was not considered a medical device by definition.269 The FDA
began to give attention to the kit when it “began to provide customized
health reports” to its users. 270 What was concerning about this was the risk
to users regarding the AI learning and knowledge component. 271 23andMe is
a prime example of why AI in healthcare offers a scare to regulatory
authority; all the knowledge provided by AI is based on models and
algorithms—models that are based on code. 272
Another risk that comes with the regulation of AI in healthcare “is
that the[se] models are based on such . . . large volume[s] of data and are so
complex that no one really knows what is driving [the] outcomes, why one
patient falls into one group or another according to the model.” 273 The
algorithms that drive ML and DL are written by humans and, while the
systems learn on their own from there, if a bad code is written—or bad data
is fed into the system—we have yet to learn how long it will take before that
self-learning system will harm itself or the patients that are using it. 274
Consistency and accuracy is a key function in not only technology, but also
in medication treatment and diagnosis. 275 If data sets are trained or coded to
encounter a limited number of or certain types of illnesses in the medical
world, it is very likely that in a clinical setting they will come across
scenarios they have never learned or been coded for. 276 The FDA will have
to reach out to other regulatory bodies to help it understand and consider all
the aspects of AI technologies, including everything from “ethics [and]
computing [to] clinical care.” 277
V.

CONCLUSION

“With such a controversial technology such as [AI], it is imperative
that policymakers make decisions while the technology is still young, before
268.
Bambauer, supra note 11, at 388; Lee & Kesselheim, supra note 253, at
730; Yates, supra note 264.
269.
Bambauer, supra note 11, at 388.
270.
Id.
271.
Id.
272.
See id.; Jones, supra note 38; Tuma, supra note 137.
273.
Tuma, supra note 137.
274.
See id.; Jones, supra note 38.
275.
Sobia Hamid, The Opportunities and Risks of Artificial Intelligence in
Medicine and Healthcare, CAMBRIDGE U. SCI. & POL’Y EXCHANGE, Summer 2016, at 1, 2.
276.
Id.
277.
Tuma, supra note 137.

https://nsuworks.nova.edu/nlr/vol43/iss3/6

30

Van Embden: Paging Dr. Robot: Applying an Outdated, Regulated Scheme to Robot

2019]

PAGING DR. ROBOT

417

they are forced to make policy reactively.” 278 The application of AI
technologies such as ML and DL to healthcare devices and drugs has been
rampant in the last ten years—ranging from telemedicine to cancer detection
to algorithms to help neurovascular brain deterioration. 279 With over $1.7
billion spent in 2016 alone on AI technologies in the healthcare industry, it is
no longer just a choice for the FDA to start developing a framework on how
to regulate ML and DL products in the context of medicine. 280 However, the
FDA should not approach these regulations alone, as the speed at which AI
continues to grow proves to be too fast for one regulatory body to handle. 281
Instead, multiple regulatory bodies should review the potential harms of
regulatory flexibility pertaining to AI technologies being applied to medical
devices and drugs and err on the side of caution. 282
Looking back at the history of the FDA, it is easy to identify a
pattern of how the agency approaches the regulation of new technologies and
drug developments. 283 Instead of having foresight and getting ahead of
innovation, the FDA allows itself to fall behind—warranting catastrophe to
stockpile up into public health events—ultimately triggering overly tight
regulations. 284 But this time, there is a technological revolution in front of
its eyes—the FDA’s way of handling changes in how drugs and medical
devices are regulated will not be able to keep up if the agency continues to
let itself fall behind. 285 The age of AI has arrived. 286

278.
Hamid, supra note 275, at 4.
279.
See Ashok, supra note 18; Mary Bates, Deep Learning Algorithms Can
Detect Subtle Brain Lesions, BIOENGINEERING TODAY: BRAIN (Mar. 9, 2018),
http://www.bioengineeringtoday.org/brain/deep-learning-algorithms-can-detect-subtle-brainlesions.
280.
Ashok, supra note 18; Tuma, supra note 137; Worldwide Spending on
Cognitive and Artificial Intelligence Systems Will Grow to $19.1 Billion in 2018, According to
New IDC Spending Guide, BUS. WIRE (Mar. 22, 2018, 11:15 AM),
http://www.businesswire.com/news/home/20180322005847/en/Worldwide-SpendingCognitive-Artificial-Intelligence-Systems-Grow.
281.
Tuma, supra note 137.
282.
Id.
283.
Id.
284.
Id.
285.
Id.; Yates, supra note 264.
286.
See Ashok, supra note 18; Tuma, supra note 137.
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